{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Dextrose&page=12",
    "query": {
      "intervention": "Oral Dextrose",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 612,
    "total_pages": 62,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Dextrose&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Dextrose&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T02:04:26.364Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05404711",
      "title": "Continuous Glucose Monitors (CGM) for Type 2 Diabetes (T2D) Risk Evaluation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Overweight and Obesity",
        "PreDiabetes",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "CGM",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Mary Ellen Vajravelu, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "8 Years to 18 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-10-11",
      "completion_date": "2023-12-14",
      "has_results": true,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-11-19T02:04:26.364Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05404711"
    },
    {
      "nct_id": "NCT00469833",
      "title": "Insulin Secretion in Diabetes Before and After Glycemic Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes",
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "30 Years to 65 Years"
      },
      "enrollment_count": 17,
      "start_date": "2008-04",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2015-01-15",
      "last_synced_at": "2026-11-19T02:04:26.364Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00469833"
    },
    {
      "nct_id": "NCT07797335",
      "title": "AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Cardiovascular Risk"
      ],
      "interventions": [
        {
          "name": "Zenagamtide",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine U-100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 1778,
      "start_date": "2026-08-24",
      "completion_date": "2028-09-20",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-11-19T02:04:26.364Z",
      "location_count": 109,
      "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 91 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Lancaster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07797335"
    },
    {
      "nct_id": "NCT02058147",
      "title": "Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Insulin glargine/lixisenatide Fixed Ratio Combination",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine (HOE901)",
          "type": "DRUG"
        },
        {
          "name": "Lixisenatide (AVE0010)",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1170,
      "start_date": "2014-02",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-11-19T02:04:26.364Z",
      "location_count": 118,
      "location_summary": "Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02058147"
    },
    {
      "nct_id": "NCT02520258",
      "title": "Study of the Reversibility of Glucose Intolerance Caused by Chronic Aspartame Consumption",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glucose Metabolism Disorder"
      ],
      "interventions": [
        {
          "name": "Oral glucose tolerance test (OGTT)",
          "type": "OTHER"
        },
        {
          "name": "Diet soda containing aspartame only",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Rockefeller University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 75,
      "start_date": "2015-08",
      "completion_date": "2019-06-25",
      "has_results": false,
      "last_update_posted_date": "2020-06-04",
      "last_synced_at": "2026-11-19T02:04:26.364Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02520258"
    },
    {
      "nct_id": "NCT00528879",
      "title": "A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "77 Years",
        "sex": "ALL",
        "summary": "18 Years to 77 Years"
      },
      "enrollment_count": 915,
      "start_date": "2007-09",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2015-10-20",
      "last_synced_at": "2026-11-19T02:04:26.364Z",
      "location_count": 28,
      "location_summary": "Tempe, Arizona • Encino, California • Fresno, California + 24 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00528879"
    },
    {
      "nct_id": "NCT06609356",
      "title": "Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus",
        "Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY)",
        "MODY2 Diabetes",
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Study Visit 1",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Study Visit 2",
          "type": "PROCEDURE"
        },
        {
          "name": "Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 27,
      "start_date": "2025-07-03",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-11-19T02:04:26.364Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06609356"
    },
    {
      "nct_id": "NCT04294966",
      "title": "Age-Related Effects of THC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Tolerance",
        "Adolescent Behavior",
        "THC"
      ],
      "interventions": [
        {
          "name": "Dextrose",
          "type": "DRUG"
        },
        {
          "name": "Dronabinol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-03-10",
      "completion_date": "2021-05-01",
      "has_results": true,
      "last_update_posted_date": "2023-11-09",
      "last_synced_at": "2026-11-19T02:04:26.364Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04294966"
    },
    {
      "nct_id": "NCT05159427",
      "title": "Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Gastrointestinal Physiology Data"
      ],
      "interventions": [
        {
          "name": "Glucotrol XL 5Mg Extended-Release Tablet",
          "type": "DRUG"
        },
        {
          "name": "Glipizide ER 5 MG 24 HR Extended Release Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin 200Mg Tab",
          "type": "DRUG"
        },
        {
          "name": "13C6-Glipizide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2022-03-15",
      "completion_date": "2026-03-29",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-11-19T02:04:26.364Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05159427"
    },
    {
      "nct_id": "NCT03013985",
      "title": "Glargine U300 Hospital Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Glargine U300",
          "type": "DRUG"
        },
        {
          "name": "Glargine U100",
          "type": "DRUG"
        },
        {
          "name": "Glulisine Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 247,
      "start_date": "2017-05-17",
      "completion_date": "2019-03-22",
      "has_results": true,
      "last_update_posted_date": "2020-05-07",
      "last_synced_at": "2026-11-19T02:04:26.364Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Minneapolis, Minnesota • Cleveland, Ohio",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03013985"
    }
  ]
}